The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Included are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug development and research.
This week we highlight an interview with Dr. Andrew Vernon, the Chief, Clinical Research Branch, Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention (CDC). He discusses the progress made in TB drug development and the growing number of TB trials and trials groups.
We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2011 at the Grand Palais in Lille, France, on October 26. Also, we are sponsoring a dinner on October 25 at Le Barbue d’Anvers in Lille to allow our Sub-groups (Biology/Targets, Candidates, Critical Knowledge and Tools, and Clinical Trial Capacity) to meet and plan for activities for 2012. Please make plans to attend both events.
Over the last week, some announcements have been released concerning new tools, publications and meeting materials that may be of value to the TB community including materials from the WGND sponsored “Essentiality of Pyrazinamide” Workshop, an interactive map of clinical trials from PACTR, and a new Collaborative Framework for Care and Control of Tuberculosis and Diabetes from the WHO and The Union.
This week’s interview is with Dr. Armand Van Deun who was the recipient of the 2010 Stop TB Partnership-Kochon Foundation prize. Last year, Dr. Van Deun, et al., published an article in the American Journal of Respiratory and Critical Care Medicine entitled “Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis”. In the interview, we discuss this article which presents the results of an observational study in Bangladesh of a treatment for multidrug-resistant TB that incorporates fourth-generation fluoroquinolone combined with other second-line drugs and supplemented by potentially still active first-line drugs. Additional links to TB R&D News are included.
“Bring Tuberculosis Out Of The Dark Into Light…” so said Gerry Elsdon, the very svelte TV broadcaster from South Africa, during the 10th anniversary celebrations of the Global Alliance for TB Drug Development (TB Alliance), during the 41st Union World Conference on Lung Health, Berlin, Germany (11-15 November 2010).